Trials / Completed
CompletedNCT00130169
A Phase 1 Open-Label Study of E7974 Administered on Days 1 and 15 of a 28-Day Cycle in Patients With Solid Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Eisai Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the maximum tolerated dose (MTD) of E7974 administered on Days 1 and 15 of a 28-day cycle in subjects with solid malignancies that have progressed following effective therapy or for which no effective therapy exists.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | E7974 | Maximum Tolerated Dose defined as 0.35 mg/m\^2 administered on Days 1 and 15 only of a 28-day cycle; the E7974 compound is administered as a bolus infusion; no placebo is given. |
Timeline
- Start date
- 2006-01-01
- Primary completion
- 2009-08-01
- Completion
- 2009-08-01
- First posted
- 2005-08-15
- Last updated
- 2015-07-01
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00130169. Inclusion in this directory is not an endorsement.